May 9
IN THIS ISSUE / MAY 9, 2018
- FDA grants lidocaine HCL 1% approval to Spectra Medical
- AAD Board selects Daniel D. Bennett, MD, as next assistant secretary-treasurer
- Hawaii passes legislation banning sunscreen with oxybenzone and octinoxate
- Study shows reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel
- Academy Advisory Board invites members to submit policy resolutions
- 2019 committee appointment application now open
FDA grants lidocaine HCL 1% approval to Spectra Medical
The U.S. Food and Drug Administration has granted Spectra Medical Devices approval to market and sell lidocaine hydrochloride 1%. According to Spectra, 5 ml glass ampules of lidocaine HCL 1% will be available for sale on May 11.
Dermatologists and their patients continue to be adversely impacted by drug shortages. The American Academy of Dermatology Association is engaged with stakeholders, including manufacturers, suppliers, the FDA, and Congress to facilitate access for patient care.
Related Links:
- What local anesthesia use is supported by evidence? – Dermatology World (March 2016)
- Running on empty – Dermatology World (July 2012)
AAD Board selects Daniel D. Bennett, MD, as next assistant secretary-treasurer
At its April 28 meeting, the American Academy of Dermatology Board of Directors selected Daniel D. Bennett, MD, as the Academy’s next assistant secretary-treasurer. He will succeed Marta Van Beek, MD, MPH, for a three-year term that will begin at the conclusion of the March 2019 Annual Meeting. (Dr. Van Beek will become secretary-treasurer at that time.) Dr. Bennett is on the faculty at the University of Wisconsin School of Medicine and Public Health. He completed his dermatology residency at the University of Texas Southwestern Medical Center and his dermatopathology fellowship at the University of Pennsylvania. Dr. Bennett currently serves as chair of the Academy’s Mohs Micrographic Surgery Committee and deputy chair of the Regulatory Policy Committee and is a member of the Drug Pricing and Transparency Task Force.
Hawaii passes legislation banning sunscreen with oxybenzone and octinoxate
The Hawaii legislature has passed a bill that bans the sale of sunscreens that contain the ingredients oxybenzone and octinoxate. According to the bill language, these ingredients “have significant harmful impacts on Hawaii’s marine environment and residing ecosystems.” If Gov. David Ige (D) signs the bill it will go into effect in 2021. The AADA and the Hawaii Dermatological Society opposed this legislation. The Academy will be issuing a letter of opposition to Gov. Ige.
There are several sunscreen ingredients that are not approved for use in the United States. Read more about these ingredients and where things stand in the approval pipeline in Dermatology World.
Related Links:
- Do European sunscreens outperform those in the U.S.? – Dermatology World (October 2017)
- Are teens tanning less? Signs point to progress, but work remains – Dermatology World (May 2018)
- What do you ask your skin cancer patients at follow up visits? – Dermatology World (July 2017)
Study shows reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel
According to a study published in the American Journal of Clinical Dermatology, topical adapalene 0.3% and benzoyl peroxide 2.5% prevented and reduced atrophic scar formation in patients with moderate or severe facial acne. Researchers conducted a 24-week, randomized, vehicle-controlled trial using intra-individual comparisons and found that scar count increased with the vehicle by 14.4% and decreased with adapalene 0.3% and benzoyl peroxide 2.5% gel by 15.5% over the course of the study.
Read more about the clinical and practical aspects of acne management in Dermatology World.
Related Links:
- What do you ask your acne patients at follow-up visits? – Dermatology World (November 2017)
- Overusing acne antibiotics? – Dermatology World (August 2015)
- What role should high-dose isotretinoin have in acne treatment? – Dermatology World (June 2014)
- Comparing therapies for pre-adolescent acne – Dermatology World (March 2014)
Academy Advisory Board invites members to submit policy resolutions
The Academy’s Advisory Board invites all AAD members as well as state, local, and specialty dermatology groups to submit proposed AAD/A policy resolutions on issues of interest and/or concern. The Advisory Board convenes to deliberate on issues of importance to individual practitioners, and if approved, propose them to the Academy’s Board of Directors for consideration. To view the Academy’s current position statements visit staging.aad.org/Forms/Policies/ps.aspx.
To ensure full consideration, all resolutions must be submitted by June 7. The author and/or their Advisory Board representative must submit an updated conflict of interest and a statement of support with their resolution for consideration by the full Advisory Board. The statement should state the reasons why the Advisory Board should adopt the resolution. The full Advisory Board will consider the submitted comments and resolutions and then vote in the fall. For general questions or to submit a resolution, contact Ashley John at ajohn@aad.org.
2019 committee appointment application now open
Every year, hundreds of dermatologists serve the Academy through its organizational governance structure and through other service opportunities. The Appointment Selection Committee, chaired by George J. Hruza, MD, MBA, has begun accepting applications to fill 2019 open appointments. Applications must be submitted by June 30, 2018. Members who are selected to serve will be contacted in the winter. Letters of recommendation are highly suggested but are not required.
